Affiliation:
1. Division of Pulmonary and Critical Care Medicine and Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205-2196; and Department of Critical Care, Medical School of Athens University, Evangelismos Hospital, Athens, Greece GR106 76
Abstract
Kotanidou, Anastasia, Augustine M. K. Choi, Richard A. Winchurch, Leo Otterbein, and Henry E. Fessler. Urethan anesthesia protects rats against lethal endotoxemia and reduces TNF-α release. J. Appl. Physiol. 81(5): 2304–2311, 1996.—Urethan is a commonly used animal anesthetic for nonrecovery laboratory surgery. However, urethan has diverse biological effects that may complicate the interpretation of experimental findings. This study examined the effect of urethan on the response to an intravenous bolus of lipopolysaccharide (LPS; 30 mg/kg) in rats. In instrumented rats, urethan (1.2 gm/kg ip) completely prevented the fall in arterial pressure immediately after LPS administration but did not prevent late cardiovascular collapse. In uninstrumented rats, urethan also attenuated indexes of organ injury measured 4 h after LPS administration, including mural bowel hemorrhage, hemoconcentration, hypoglycemia, metabolic acidosis, and lung myeloperoxidase activity, a measure of neutrophil sequestration. The peak increase in tumor necrosis factor-α (TNF-α) 90 min after LPS administration was reduced 88% by urethan (2,060 ± 316 vs. 16,934 ± 847 pg/ml; P < 0.001). In uninstrumented animals, urethan at 1.2 gm/kg reduced the 90% mortality rate of a lethal dose of LPS to 0–10% when given up to 24 h before LPS administration but did not reduce mortality when given 2 h after LPS. Urethan neither directly bound LPS by Limulus assay nor inhibited LPS-stimulated TNF-α mRNA expression in cultured mouse peritoneal macrophages, but TNF-α mRNA expression was suppressed by serum from a urethan-treated rat. Moreover, rauwolscine, which shares α2-adrenoceptor-blocking activity with urethan, also prevented death from a subsequent 90% lethal dose LPS bolus. We conclude that urethan or its metabolites protect against LPS, in part, by reducing TNF-α release and speculate that this may be mediated by α2-adrenoceptors. These actions of urethan make it an undesirable anesthetic agent for in vivo studies of sepsis or LPS.
Publisher
American Physiological Society
Subject
Physiology (medical),Physiology
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献